TY - JOUR
T1 - Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management
T2 - A PIONEER Analysis Based on Big Data
AU - Gandaglia, Giorgio
AU - Pellegrino, Francesco
AU - Golozar, Asieh
AU - De Meulder, Bertrand
AU - Abbott, Thomas
AU - Achtman, Ariel
AU - Imran Omar, Muhammad
AU - Alshammari, Thamir
AU - Areia, Carlos
AU - Asiimwe, Alex
AU - Beyer, Katharina
AU - Bjartell, Anders
AU - Campi, Riccardo
AU - Cornford, Philip
AU - Falconer, Thomas
AU - Feng, Qi
AU - Gong, Mengchun
AU - Herrera, Ronald
AU - Hughes, Nigel
AU - Hulsen, Tim
AU - Kinnaird, Adam
AU - Lai, Lana Y H
AU - Maresca, Gianluca
AU - Mottet, Nicolas
AU - Oja, Marek
AU - Prinsen, Peter
AU - Reich, Christian
AU - Remmers, Sebastiaan
AU - Roobol, Monique J
AU - Sakalis, Vasileios
AU - Seager, Sarah
AU - Smith, Emma J
AU - Snijder, Robert
AU - Steinbeisser, Carl
AU - Thurin, Nicolas H
AU - Hijazy, Ayman
AU - van Bochove, Kees
AU - Van den Bergh, Roderick C N
AU - Van Hemelrijck, Mieke
AU - Willemse, Peter-Paul
AU - Williams, Andrew E
AU - Zounemat Kermani, Nazanin
AU - Evans-Axelsson, Susan
AU - Briganti, Alberto
AU - N'Dow, James
N1 - Publisher Copyright:
© 2023 The Author(s)
PY - 2024/5
Y1 - 2024/5
N2 - BACKGROUND: Conservative management is an option for prostate cancer (PCa) patients either with the objective of delaying or even avoiding curative therapy, or to wait until palliative treatment is needed. PIONEER, funded by the European Commission Innovative Medicines Initiative, aims at improving PCa care across Europe through the application of big data analytics.OBJECTIVE: To describe the clinical characteristics and long-term outcomes of PCa patients on conservative management by using an international large network of real-world data.DESIGN, SETTING, AND PARTICIPANTS: From an initial cohort of >100 000 000 adult individuals included in eight databases evaluated during a virtual study-a-thon hosted by PIONEER, we identified newly diagnosed PCa cases (n = 527 311). Among those, we selected patients who did not receive curative or palliative treatment within 6 mo from diagnosis (n = 123 146).OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patient and disease characteristics were reported. The number of patients who experienced the main study outcomes was quantified for each stratum and the overall cohort. Kaplan-Meier analyses were used to estimate the distribution of time to event data.RESULTS AND LIMITATIONS: The most common comorbidities were hypertension (35-73%), obesity (9.2-54%), and type 2 diabetes (11-28%). The rate of PCa-related symptomatic progression ranged between 2.6% and 6.2%. Hospitalization (12-25%) and emergency department visits (10-14%) were common events during the 1st year of follow-up. The probability of being free from both palliative and curative treatments decreased during follow-up. Limitations include a lack of information on patients and disease characteristics and on treatment intent.CONCLUSIONS: Our results allow us to better understand the current landscape of patients with PCa managed with conservative treatment. PIONEER offers a unique opportunity to characterize the baseline features and outcomes of PCa patients managed conservatively using real-world data.PATIENT SUMMARY: Up to 25% of men with prostate cancer (PCa) managed conservatively experienced hospitalization and emergency department visits within the 1st year after diagnosis; 6% experienced PCa-related symptoms. The probability of receiving therapies for PCa decreased according to time elapsed after the diagnosis.
AB - BACKGROUND: Conservative management is an option for prostate cancer (PCa) patients either with the objective of delaying or even avoiding curative therapy, or to wait until palliative treatment is needed. PIONEER, funded by the European Commission Innovative Medicines Initiative, aims at improving PCa care across Europe through the application of big data analytics.OBJECTIVE: To describe the clinical characteristics and long-term outcomes of PCa patients on conservative management by using an international large network of real-world data.DESIGN, SETTING, AND PARTICIPANTS: From an initial cohort of >100 000 000 adult individuals included in eight databases evaluated during a virtual study-a-thon hosted by PIONEER, we identified newly diagnosed PCa cases (n = 527 311). Among those, we selected patients who did not receive curative or palliative treatment within 6 mo from diagnosis (n = 123 146).OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patient and disease characteristics were reported. The number of patients who experienced the main study outcomes was quantified for each stratum and the overall cohort. Kaplan-Meier analyses were used to estimate the distribution of time to event data.RESULTS AND LIMITATIONS: The most common comorbidities were hypertension (35-73%), obesity (9.2-54%), and type 2 diabetes (11-28%). The rate of PCa-related symptomatic progression ranged between 2.6% and 6.2%. Hospitalization (12-25%) and emergency department visits (10-14%) were common events during the 1st year of follow-up. The probability of being free from both palliative and curative treatments decreased during follow-up. Limitations include a lack of information on patients and disease characteristics and on treatment intent.CONCLUSIONS: Our results allow us to better understand the current landscape of patients with PCa managed with conservative treatment. PIONEER offers a unique opportunity to characterize the baseline features and outcomes of PCa patients managed conservatively using real-world data.PATIENT SUMMARY: Up to 25% of men with prostate cancer (PCa) managed conservatively experienced hospitalization and emergency department visits within the 1st year after diagnosis; 6% experienced PCa-related symptoms. The probability of receiving therapies for PCa decreased according to time elapsed after the diagnosis.
KW - Big data
KW - Conservative management
KW - Outcomes
KW - PIONEER
KW - Prostate cancer
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85164440972&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2023.06.012
DO - 10.1016/j.eururo.2023.06.012
M3 - Article
C2 - 37414703
SN - 0302-2838
VL - 85
SP - 457
EP - 465
JO - European Urology
JF - European Urology
IS - 5
ER -